Safety of Recombinant Human Bone Morphogenetic Protein-2 Versus Iliac Crest Bone Graft in Alveolar Cleft Repair: Systematic Review and Meta-Analysis
The Cleft Palate Craniofacial Journal · 17.11.2026
DOI: 10.1177/10556656261507944 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Cleft Palate Craniofacial Journal, online erschienen am 17.11.2026. Verfasst von Abdulla Alhamdan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Queen Mary University of London, London, UK. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To compare the safety and complication profiles of recombinant human bone morphogenetic protein (rhBMP-2) and iliac crest bone graft (ICBG) in alveolar cleft repair.
Design
A systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and prospectively registered with PROSPERO ( CRD420261340773) .
Setting
Published comparative studies identified through a comprehensive search of PubMed/MEDLINE, Embase and CENTRAL up to September 2026. Patients, Participants 808 patients undergoing alveolar cleft repair, 395 with ICBG, 413 with rhBMP-2; across 7 studies (2 RCTs, 5 observational studies).
Interventions
RhBMP-2 versus ICBG. Main Outcome Measures Primary outcomes are graft failure, infection, oronasal fistula formation, postoperative swelling and wound dehiscence; secondary outcomes were operative time, length of stay and cost.
Results
Seven studies were included in the analysis. There were no statistically significant differences observed in graft failure (odds ratio [OR] = 0.86, 95% confidence interval [CI] 0.43-1.71, P = 0.67), wound dehiscence (OR = 1.33; 0.57-3.14) and fistula formation (OR = 0.46; 0.04-5.05). RhBMP-2 was associated with lower postoperative infection rates (OR = 0.20; 0.05-0.72; P = 0.01), although it was also associated with higher postoperative swelling (OR = 9.74, 95% CI 3.91-24.27, P < 0.00001). However, certainty of the evidence remained low.
Conclusions
Although rhBMP-2 may be associated with lower infection rates, the increased postoperative swelling risk remains a concern. The limited number of studies, predominantly observational evidence, imprecision and heterogeneity limit the interpretation of these findings. Adequately powered RCTs are needed to establish the safety of rhBMP-2 relative to ICBG.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Queen Mary University of London, London, UK.
- School of Medicine, University of Lancashire, Preston, UK.
- Division of Plastic, Reconstructive and Aesthetic Surgery, McGill University Health Center, Montreal, Canada.
ORCID-Profile: Efthimios Demetriou, Mohammad Almeer, Christoforos Demosthenous, Hiba Nura Miyir
Zitieren
APA
Alhamdan, A., Demetriou, E., Almeer, M., Demosthenous, C., Miyir, H. N., & Zammit, D. (2026). Safety of Recombinant Human Bone Morphogenetic Protein-2 Versus Iliac Crest Bone Graft in Alveolar Cleft Repair: Systematic Review and Meta-Analysis. The Cleft Palate Craniofacial Journal. https://doi.org/10.1177/10556656261507944
Vancouver
Alhamdan A, Demetriou E, Almeer M, Demosthenous C, Miyir HN, Zammit D. Safety of Recombinant Human Bone Morphogenetic Protein-2 Versus Iliac Crest Bone Graft in Alveolar Cleft Repair: Systematic Review and Meta-Analysis. The Cleft Palate Craniofacial Journal. 2026. doi:10.1177/10556656261507944
BibTeX
@article{Alhamdan2026,
author = {Alhamdan, Abdulla and Demetriou, Efthimios and Almeer, Mohammad and Demosthenous, Christoforos and Miyir, Hiba Nura and Zammit, Dino},
title = {Safety of Recombinant Human Bone Morphogenetic Protein-2 Versus Iliac Crest Bone Graft in Alveolar Cleft Repair: Systematic Review and Meta-Analysis},
journal = {The Cleft Palate Craniofacial Journal},
year = {2026},
doi = {10.1177/10556656261507944}
}
EUVIMED